CA9 and neoplasm: Furthermore, retrospective analysis of HNSCC patient samples treated with immunotherapy either as front-line therapy or following platinum failure found that patients, with higher %CA9/mean intensity (%CA9/I) associated with more hypoxic tumours, had reduced efficacy of anti-PD-1 therapy.